비아트리즈(VTRS) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

VTRS

Viatris Inc

7월 27일 1:48 PM ET (한국 7/28 02:48)

$17.24

-0.04 ▼ -0.23%

비아트리즈(VTRS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$20.2B

미드캡

P/E

배당수익률

3.01%

52주 위치

95%

저점 +100% · 고점 -2%

애널리스트

매수

Fundamental health

vs. Drug Manufacturers - Specialty & Generic

수익성

Top 48%

성장

Top 61%

밸류에이션

Top 72%

재무 안정

Top 48%

Index ⓘ	S&P 500	P/E ⓘ	-	EPS (ttm) ⓘ	-0.26	Insider Own ⓘ	2.02%	Shs Outstand ⓘ	1.16B	Perf Week ⓘ	-0.29%
Market Cap ⓘ	20.23B	Forward P/E ⓘ	6.55	EPS next Y ⓘ	7.38%	Insider Trans ⓘ	-0.3%	Shs Float ⓘ	1.15B	Perf Month ⓘ	8.22%
Enterprise Value ⓘ	32.59B	PEG ⓘ	0.96	EPS next Q ⓘ	0.6	Inst Own ⓘ	85.15%	Short Float ⓘ	4.18%	Perf Quarter ⓘ	16.88%
Income ⓘ	-0.30B	P/S ⓘ	1.39	EPS this Y ⓘ	4.29%	Inst Trans ⓘ	1.81%	Short Ratio ⓘ	4.35	Perf Half Y ⓘ	30.21%
Sales ⓘ	14.57B	P/B ⓘ	1.37	EPS next 5Y ⓘ	6.79%	ROA ⓘ	-0.79%	Short Interest ⓘ	48.02M	Perf YTD ⓘ	38.47%
Book/sh ⓘ	12.59	P/C ⓘ	8.95	EPS past 3/5Y ⓘ	- -21.93%	ROE ⓘ	-1.96%	52W High ⓘ	-2.46% ($17.67)	Perf Year ⓘ	84.39%
Cash/sh ⓘ	1.93	P/FCF ⓘ	11.29	Sales past 3/5Y ⓘ	-4.04% 3.66%	ROIC ⓘ	-1.09%	52W Low ⓘ	99.88% ($8.62)	Perf 3Y ⓘ	62.34%
Dividend Est. ⓘ	$0.52 (3.01%)	EV/EBITDA ⓘ	7.91	EPS Y/Y TTM ⓘ	91.93%	Gross Margin ⓘ	38.9%	Volatility(W/M) ⓘ	3.58% 2.91%	Perf 5Y ⓘ	23.85%
Dividend TTM ⓘ	0.48	EV/Sales ⓘ	2.24	Sales Y/Y TTM ⓘ	2.14%	Oper. Margin ⓘ	9%	ATR (14) ⓘ	0.51	Perf 10Y ⓘ	-63%
Dividend Ex-Date ⓘ	2026/5/22	Quick Ratio ⓘ	0.94	EPS Q/Q ⓘ	105.88%	Profit Margin ⓘ	-2.04%	RSI (14) ⓘ	58.16	Recom ⓘ	2.42
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1.52	Sales Q/Q ⓘ	8.5%	SMA20 ⓘ	3.09% ($16.72)	Beta ⓘ	0.89	Target Price ⓘ	$18.14
Payout ⓘ	-	Debt/Eq ⓘ	1	Earnings ⓘ	2026/8/6	SMA50 ⓘ	5.25% ($16.38)	Rel Volume ⓘ	0.67	Prev Close ⓘ	$17.28
Employees ⓘ	30000	LT Debt/Eq ⓘ	0.86	EPS/Sales Surpr. ⓘ	17.58% 4.77%	SMA200 ⓘ	25.35% ($13.75)	Avg Volume(3M) ⓘ	11.03M	Price ⓘ	$17.24
IPO ⓘ	1980/3/17	Option/Short ⓘ	Yes/Yes			Trades ⓘ	28576	Volume ⓘ	7,367,013	Change ⓘ	-0.23%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $3.5B (YoY +8%) · 순이익 -

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Viatris Inc (VTRS) Investment Analysis

What kind of company is Viatris Inc?

비아트리즈(VTRS) 배당주

Healthcare · Drug Manufacturers - Specialty & Generic

#610 by Market Cap — Mid-Cap

💊 A pharmaceutical company that supplies generics (copy drugs) and specialty pharmaceuticals globally. It holds a broad portfolio of generics, biosimilars, and branded drugs across various therapeutic areas, supplying medicines to markets around the world. It is one of the leading generic and specialty pharmaceutical companies with an extensive product portfolio and global distribution network.

Learn more about Viatris Inc →

Market Cap

$20.2B

Approx. KRW 27.7 trillion

⚖️ 7% of Samsung Electronics

Market Cap Rank610

Employees30,000people

IPO1980/03/17

Current Price$17.24 ≈ 23,619원

📌 S&P 500 · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-10

8월 6일 (목) · 장 시작 전

예상 EPS $0.60

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🎯 Ex-div 2026년 5월 22일 (금) 주당 $0.12

🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS +17.6% 매출 +4.8%

🎯 Ex-div 2026년 3월 9일 (월) 주당 $0.12

🔔 Earnings release 2026년 2월 26일 (목) · 장 시작 전 EPS +7.1% 매출 +4.8%

Is it profitable?

Profitability weak

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

9.0%

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median -7.1% · Top 31%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

-2.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

38.9%

✓ 평균

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 52.5% · Bottom 35%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-2.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-0.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-1.1%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

1.00

✓ Average

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 0.36

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

1.52

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 2.47

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.94

✓ 평균

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 1.68

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$18.14

현재가 대비 +5.2%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

6.55배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

0.96

저평가

💡 PEG < 1 — 성장 대비 저렴

내년 EPS 예상 성장률

+7.4%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+6.8%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability

Beat estimates in 2 of the last 2 quarters

예상 상회

예상 부합

예상 하회

100%

상회 비율

+12.5%

평균 서프라이즈

2026.05.07

상회

실적 $0.59 · 예상 $0.50 +17.5%

2026.02.26

상회

실적 $0.57 · 예상 $0.53 +7.4%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+4.3%

평균

My positionMid-range

Low range Average High range

배당주 대형주 Median 5.5% · Bottom 46%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+7.4%

양호

My positionMid-range

Low range Average High range

배당주 대형주 Median 7.3% · Top 49%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+6.8%

양호

My positionMid-range

Low range Average High range

배당주 대형주 Median 6.7% · Top 49%

📊 How much has it grown? (actual results)

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

-21.9%

매우 부진

My positionBottom 5%

Low range Average High range

배당주 대형주 Median 6.3% · Bottom tier

Past 5-Year Revenue

How much revenue grew over the past 5 years

+3.7%

평균

My positionMid-range

Low range Average High range

배당주 대형주 Median 6.7% · Bottom 25%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+8.5%

양호

My positionMid-range

Low range Average High range

배당주 대형주 Median 5.9% · Top 38%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -44%p below the market

VTRS +23.9% · S&P 500 +68.0%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-44.1%p

Significantly behind the market

vs Health Care (XLV)

+0.2%p

roughly in line with the sector average

1-year basis

vs S&P 500

+67.9%p

well ahead of the market

vs Health Care (XLV)

+64.6%p

well ahead of the sector average

Rank among peers

1-year return Top 19% Based on 10 peers

Current position within 52-week range

Low (-99.9%p) High (-2.5%p)

Current price is 99.9% above the 52-week low and 2.5% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-19.7%

Annualized volatility

34.4%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-24

Uptrend zone

Current price $17.24 above the midline ($16.72). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢

Current diagnosis · 2026-07-24

Bullish momentum holding

MACD 0.314 > Signal 0.262 in positive zone + Hist positive (+0.052). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-24

Bullish zone

RSI 58.2 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 75.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

6.55x

✓ Very cheap

My positionTop 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 14.70x · Top 16% — relatively cheap within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

1.37x

✓ Cheap

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic median 1.55x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

1.39x

✓ Cheap

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic median 2.13x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

7.91x

✓ Very cheap

My positionTop 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 10.57x · Top 21% — relatively cheap within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

11.29x

✓ Cheap

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic median 18.10x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$18.14 vs. current price +5.2%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic

Who owns it?

Ownership flow is positive

Insider modest net selling -0.3% · Institutional net buying +1.8% · Short interest light 4.2% · Short interest up +1.7pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-0.3%

Insiders net selling

🏦 Institutions (funds & investors)

+1.8%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 85.2%

Institution-led, stable structure

Healthcare 대형주 Median 91.9%

🧑‍💼 Insiders 2.0%

Typical level

Healthcare 대형주 Median 0.8%

👤 Retail investors (estimated) 12.8%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

4.2%

Low — limited short-side pressure

Healthcare 대형주 Median 3.6%

Past 90 days 📈 +1.7%p increase

Short interest days to cover

4.3 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 1.16B주

Float (tradable shares) 1.15B주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding VTRS

ETFs with the highest weightings · 10 total shown

DUSA

Davis Select U.S. Equity ETF

4.97%

$1.3B

IHE

iShares U.S. Pharmaceuticals ETF

Davis Select Worldwide ETF

4.01%

$584M

FTXH

First Trust Nasdaq Pharmaceuticals ETF

3.43%

$68M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당주 — 연 3.01% 배당

Dividend Yield

3.01%

Industry average 1.25%

Dividend Per Share

$0.52

Annualized

Payout Ratio

Share of net income paid as dividends

5-Year Growth

Annualized dividend growth

📅 지급월 3월 · 8월 · 11월

📊 총 이력 1986~2026 (96건)

연도별 배당 총액 추이

주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.

$0.10 +27.1%

2003

$0.12 +25.0%

2004

$0.21 +75.0%

2005

$0.24 +14.3%

2006

$0.12 -50.0%

2007

$0.33 +175.0%

2021

$0.48 +45.5%

2022

$0.48 +0.0%

2023

$0.48 +0.0%

2024

$0.48 +0.0%

2025

$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소

최근 배당 이력 총 96건

아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.

배당락일

주당 금액

지급일

당시 수익률

2026-03-09

$0.120

—

4.22%

2025-11-24

$0.120

—

4.54%

2025-08-22

$0.120

—

5.63%

2025-05-23

$0.120

—

7.24%

2025-03-10

$0.120

—

5.05%

2024-11-22

$0.120

—

3.59%

2024-08-23

$0.120

—

4.08%

2024-05-23

$0.120

—

4.56%

2024-03-08

$0.120

—

3.92%

2023-11-22

$0.120

—

6.40%

2023-08-23

$0.120

—

5.45%

2023-05-23

$0.120

—

6.49%

2023-03-08

$0.120

—

4.55%

2022-11-22

$0.120

—

5.33%

2022-08-23

$0.120

—

5.71%

2022-05-23

$0.120

—

3.96%

2022-02-23

$0.120

—

3.14%

2021-11-22

$0.110

—

2.52%

2021-08-23

$0.110

—

1.49%

2021-05-21

$0.110

—

0.72%

2007-06-27

$0.060

—

1.62%

2007-03-28

$0.060

—

1.42%

2006-12-27

$0.060

—

1.51%

2006-09-27

$0.060

—

1.49%

2006-06-28

$0.060

—

1.46%

2006-03-29

$0.060

—

1.13%

2005-12-28

$0.060

—

1.19%

2005-09-28

$0.060

—

1.11%

2005-06-28

$0.060

—

0.93%

2005-03-29

$0.030

—

0.85%

2004-12-29

$0.030

—

0.68%

2004-09-28

$0.030

—

0.67%

2004-06-28

$0.030

—

0.56%

2004-03-29

$0.030

—

0.45%

2003-12-29

$0.030

—

0.38%

2003-09-26

$0.022

—

0.42%

2003-06-26

$0.022

—

0.44%

2003-03-27

$0.022

—

0.42%

2002-12-27

$0.022

—

0.62%

2002-09-26

$0.018

—

0.61%

2002-06-26

$0.018

—

0.67%

2002-03-26

$0.018

—

0.67%

2001-12-27

$0.018

—

0.53%

2001-09-26

$0.018

—

0.63%

2001-06-27

$0.018

—

0.71%

2001-03-28

$0.018

—

0.80%

2000-12-27

$0.018

—

0.78%

2000-09-27

$0.018

—

0.72%

2000-06-28

$0.018

—

0.92%

2000-03-29

$0.018

—

0.61%

1999-12-29

$0.018

—

0.79%

1999-09-28

$0.018

—

1.13%

1999-06-28

$0.018

—

0.63%

1999-03-29

$0.018

—

0.72%

1998-12-29

$0.018

—

0.69%

1998-09-28

$0.018

—

0.55%

1998-06-26

$0.018

—

0.63%

1998-03-30

$0.018

—

0.68%

1997-12-29

$0.018

—

0.98%

1997-09-26

$0.018

—

0.89%

1997-06-26

$0.018

—

1.34%

1997-03-26

$0.018

—

1.31%

1996-12-30

$0.018

—

0.95%

1996-09-26

$0.018

—

1.17%

1996-06-26

$0.018

—

1.13%

1996-03-27

$0.018

—

0.76%

1995-12-27

$0.018

—

0.62%

1995-09-27

$0.018

—

0.72%

1995-06-29

$0.015

—

0.67%

1995-03-27

$0.015

—

0.60%

1994-12-23

$0.018

—

0.86%

1994-09-26

$0.015

—

0.69%

1994-06-24

$0.012

—

0.89%

1994-03-25

$0.012

—

0.99%

1993-12-27

$0.012

—

0.58%

1993-09-24

$0.012

—

0.59%

1993-06-24

$0.009

—

0.51%

1993-03-25

$0.009

—

0.50%

1992-12-24

$0.009

—

0.37%

1992-09-24

$0.009

—

0.39%

1992-06-24

$0.007

—

0.55%

1992-03-25

$0.007

—

0.53%

1991-12-24

$0.007

—

0.66%

1991-09-24

$0.007

—

0.76%

1991-06-24

$0.007

—

0.99%

1991-03-22

$0.007

—

0.75%

1990-12-24

$0.007

—

0.76%

1990-09-24

$0.007

—

0.83%

1990-06-25

$0.007

—

0.66%

1989-12-22

$0.007

—

0.52%

1989-06-26

$0.007

—

1.19%

1988-12-23

$0.004

—

1.47%

1988-06-29

$0.007

—

0.77%

1987-12-24

$0.007

—

1.69%

1987-06-24

$0.007

—

0.63%

1986-12-24

$0.007

—

0.44%

* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.

💰 내가 100만원 투자한다면

연간 배당금 (세후) 2.6만원

5년 누적 (세후) 12.8만원

* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
VTRS This Stock	$20.2B	-	1.4 ▲	-1.96% ▲	3.01% ▲	-0.2%
LLY	$1.13T	43.0 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.9%
JNJ	$634.1B	30.5 ▼	7.5 ▼	25.74% ▲	2.04% ▲	+1.6%
ABBV	$458.2B	127.9 ▼	-	15221.82% ▲	2.65% ▲	+0.9%
UNH	$382.1B	27.1 ▼	3.9 ▼	12.49% ▲	2.15% ▲	-0.7%
MRK	$323.7B	36.9 ▼	7.1 ▼	18.97% ▲	2.49% ▲	+0.5%
Sector Avg	-	25.8	2.7	-48.83%	1.25%	-

FAQ

What kind of company is 비아트리즈(VTRS)?

비아트리즈(VTRS) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of VTRS?

The market cap of VTRS is approximately $20.2B, ranking 610 within its sector.

Does VTRS pay dividends?

VTRS has a dividend yield of approximately 3.01%, with an annual dividend of $0.52.

What is the 52-week high and low for VTRS?

VTRS has recorded a 52-week high of $17.67 and a low of $8.62.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.